GemVax’s highly promising Phase II Alzheimer’s disease clinical trial results targeting telomerase published in prestigious Alzheimer’s Research & Therapy’ journal

GemVax & KAEL Co., Ltd. (Korea: 082270) (“GemVax”) has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’. The paper is titled ‘Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s already receiving donepezil: a phase 2…

thaipr.net

1 เม.ย. 64

Megaport Launches Megaport Virtual Edge, an On-demand NFV Service with Immediate Support for Branch-to-Cloud Connectivity with Cisco SD-WAN Cloud Interconnect

Megaport Virtual Edge (MVE) enables businesses to modernise their network by hosting on-demand network functions natively on Megaport’s global Software Defined Network Megaport Limited (ASX: MP1) (“Megaport”), a global leading Network as a Service (NaaS) provider, today announces the launch of Megaport Virtual Edge (MVE), an on-demand vendor-neutral Network Function Virtualization (NFV) service that enables […]

thaipr.net

1 เม.ย. 64
1 3,103 3,104 3,105 3,106 3,107 3,350